
Hashem Farrokh
Examiner (ID: 16094, Phone: (571)272-4193 , Office: P/2131 )
| Most Active Art Unit | 2138 |
| Art Unit(s) | 2138, 2187, 2135, 2188, 2131 |
| Total Applications | 1266 |
| Issued Applications | 1110 |
| Pending Applications | 60 |
| Abandoned Applications | 119 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20451785
[patent_doc_number] => 12514828
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Methods of permeabilizing the blood brain barrier
[patent_app_type] => utility
[patent_app_number] => 18/984062
[patent_app_country] => US
[patent_app_date] => 2024-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 22
[patent_no_of_words] => 9541
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18984062
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/984062 | Methods of permeabilizing the blood brain barrier | Dec 16, 2024 | Issued |
Array
(
[id] => 19556516
[patent_doc_number] => 20240368308
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => ANTIBODIES TO UBIQUITIN C-TERMINAL HYDROLASE L1 (UCH-L1) AND GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 18/781407
[patent_app_country] => US
[patent_app_date] => 2024-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 98423
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18781407
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/781407 | ANTIBODIES TO UBIQUITIN C-TERMINAL HYDROLASE L1 (UCH-L1) AND GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) AND RELATED METHODS | Jul 22, 2024 | Pending |
Array
(
[id] => 19693238
[patent_doc_number] => 20250011783
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-09
[patent_title] => GENE THERAPY FOR NEURODEGENERATIVE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/743624
[patent_app_country] => US
[patent_app_date] => 2024-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11025
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18743624
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/743624 | GENE THERAPY FOR NEURODEGENERATIVE DISORDERS | Jun 13, 2024 | Abandoned |
Array
(
[id] => 20621644
[patent_doc_number] => 12589138
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-31
[patent_title] => Marker for acid sphingomyelinase disorders and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/649453
[patent_app_country] => US
[patent_app_date] => 2024-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 5
[patent_no_of_words] => 6686
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18649453
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/649453 | Marker for acid sphingomyelinase disorders and uses thereof | Apr 28, 2024 | Issued |
Array
(
[id] => 19755738
[patent_doc_number] => 20250044303
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-06
[patent_title] => PROTEIN BIOMARKER INDICATORS OF NEUROLOGICAL INJURY AND/OR DISEASE AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/645977
[patent_app_country] => US
[patent_app_date] => 2024-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28750
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18645977
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/645977 | PROTEIN BIOMARKER INDICATORS OF NEUROLOGICAL INJURY AND/OR DISEASE AND METHODS OF USE THEREOF | Apr 24, 2024 | Pending |
Array
(
[id] => 19724083
[patent_doc_number] => 20250026834
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-23
[patent_title] => FELINE ANTIBODY VARIANTS
[patent_app_type] => utility
[patent_app_number] => 18/640470
[patent_app_country] => US
[patent_app_date] => 2024-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16055
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18640470
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/640470 | FELINE ANTIBODY VARIANTS | Apr 18, 2024 | Pending |
Array
(
[id] => 19362143
[patent_doc_number] => 20240264177
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => BIOMARKER DETECTION PROCESS AND ASSAY OF NEUROLOGICAL CONDITION
[patent_app_type] => utility
[patent_app_number] => 18/637770
[patent_app_country] => US
[patent_app_date] => 2024-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11427
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637770
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/637770 | Biomarker detection process and assay of neurological condition | Apr 16, 2024 | Issued |
Array
(
[id] => 19418496
[patent_doc_number] => 20240294619
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => ANTIBODIES TO AMYLOID BETA
[patent_app_type] => utility
[patent_app_number] => 18/604668
[patent_app_country] => US
[patent_app_date] => 2024-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49539
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18604668
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/604668 | Antibodies to amyloid beta | Mar 13, 2024 | Issued |
Array
(
[id] => 19404934
[patent_doc_number] => 20240288445
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => METHOD OF DETERMINING TOXICITY OF AN IMMUNOMODULATORY DRUG FOR USE IN HUMANS
[patent_app_type] => utility
[patent_app_number] => 18/603889
[patent_app_country] => US
[patent_app_date] => 2024-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26043
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18603889
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/603889 | Method of determining toxicity of an immunomodulatory drug for use in humans | Mar 12, 2024 | Issued |
Array
(
[id] => 19685443
[patent_doc_number] => 20250003988
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-02
[patent_title] => USE OF ONE OR MORE BIOMARKERS TO DETERMINE TRAUMATIC BRAIN INJURY (TBI) IN A HUMAN SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY SCAN THAT IS NEGATIVE FOR A TBI
[patent_app_type] => utility
[patent_app_number] => 18/443416
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 144
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443416
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443416 | USE OF ONE OR MORE BIOMARKERS TO DETERMINE TRAUMATIC BRAIN INJURY (TBI) IN A HUMAN SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY SCAN THAT IS NEGATIVE FOR A TBI | Feb 15, 2024 | Abandoned |
Array
(
[id] => 19403664
[patent_doc_number] => 20240287175
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/526952
[patent_app_country] => US
[patent_app_date] => 2023-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38297
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18526952
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/526952 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES | Nov 30, 2023 | Pending |
Array
(
[id] => 19318616
[patent_doc_number] => 20240240159
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => UNIVERSAL SENSING SYSTEM
[patent_app_type] => utility
[patent_app_number] => 18/521870
[patent_app_country] => US
[patent_app_date] => 2023-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28865
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18521870
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/521870 | UNIVERSAL SENSING SYSTEM | Nov 27, 2023 | Pending |
Array
(
[id] => 19143581
[patent_doc_number] => 20240142454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => ANTIBODIES FOR BINDING PATHOLOGIC FORMS OF CALCINEURIN
[patent_app_type] => utility
[patent_app_number] => 18/520159
[patent_app_country] => US
[patent_app_date] => 2023-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15339
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18520159
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/520159 | ANTIBODIES FOR BINDING PATHOLOGIC FORMS OF CALCINEURIN | Nov 26, 2023 | Pending |
Array
(
[id] => 19097797
[patent_doc_number] => 20240117025
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY INTRANASAL ADMINISTRATION OF IMMUNOGLOBULIN G
[patent_app_type] => utility
[patent_app_number] => 18/507265
[patent_app_country] => US
[patent_app_date] => 2023-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69677
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -224
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18507265
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/507265 | Treatment of central nervous system disorders by intranasal administration of immunoglobulin G | Nov 12, 2023 | Issued |
Array
(
[id] => 19049331
[patent_doc_number] => 20240091300
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIR
[patent_app_type] => utility
[patent_app_number] => 18/506582
[patent_app_country] => US
[patent_app_date] => 2023-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17066
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18506582
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/506582 | CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIR | Nov 9, 2023 | Abandoned |
Array
(
[id] => 19403659
[patent_doc_number] => 20240287170
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => METHODS FOR TREATING SYSTEMIC SCLEROSIS
[patent_app_type] => utility
[patent_app_number] => 18/490689
[patent_app_country] => US
[patent_app_date] => 2023-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30656
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18490689
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/490689 | METHODS FOR TREATING SYSTEMIC SCLEROSIS | Oct 18, 2023 | Abandoned |
Array
(
[id] => 18940926
[patent_doc_number] => 20240036065
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => DETECTION OF DEBRIS IN RECIRCULATING PHAGOCYTES
[patent_app_type] => utility
[patent_app_number] => 18/379431
[patent_app_country] => US
[patent_app_date] => 2023-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10892
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18379431
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/379431 | DETECTION OF DEBRIS IN RECIRCULATING PHAGOCYTES | Oct 11, 2023 | Pending |
Array
(
[id] => 18973266
[patent_doc_number] => 20240053358
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => METHOD FOR ANTIBODY IDENTIFICATION FROM PROTEIN MIXTURES
[patent_app_type] => utility
[patent_app_number] => 18/481945
[patent_app_country] => US
[patent_app_date] => 2023-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10783
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481945
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/481945 | METHOD FOR ANTIBODY IDENTIFICATION FROM PROTEIN MIXTURES | Oct 4, 2023 | Pending |
Array
(
[id] => 19418787
[patent_doc_number] => 20240294910
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => NOVEL THERAPEUTIC AGENT FOR SEPTICEMIA, AND A METHOD FOR SCREENING FOR SAME
[patent_app_type] => utility
[patent_app_number] => 18/480916
[patent_app_country] => US
[patent_app_date] => 2023-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12730
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18480916
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/480916 | NOVEL THERAPEUTIC AGENT FOR SEPTICEMIA, AND A METHOD FOR SCREENING FOR SAME | Oct 3, 2023 | Pending |
Array
(
[id] => 19097842
[patent_doc_number] => 20240117070
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => RECOMBINANT ANTIBODIES, KITS COMPRISING THE SAME, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/376628
[patent_app_country] => US
[patent_app_date] => 2023-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7290
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18376628
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/376628 | RECOMBINANT ANTIBODIES, KITS COMPRISING THE SAME, AND USES THEREOF | Oct 3, 2023 | Pending |